Back to Search Start Over

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

Source :
PR Newswire. February 7, 2022
Publication Year :
2022

Abstract

ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.692202108